Leukeran (Chlorambucil)

Chlorambucil acts as an alkylating agent that binds covalently to DNA, forming cross‑links that prevent DNA strands from separating during replication. This disruption halts cell division and triggers programmed cell death, especially in rapidly proliferating cancer cells of the lymphatic system.

The dose of Leukeran is individualized by the prescribing physician based on the patient’s disease type, stage, body surface area, renal function, and blood count results. Clinicians determine the appropriate regimen and adjust it according to therapeutic response and tolerability.

Chlorambucil is classified as potentially harmful to the fetus and is generally avoided during pregnancy unless the therapeutic benefit justifies the risk. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To order Leukeran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to chlorambucil is cyclophosphamide, another alkylating agent. While both disrupt DNA, cyclophosphamide often requires intravenous administration and may have a broader toxicity profile, whereas chlorambucil is taken orally and is typically used for indolent lymphoid malignancies with a more convenient dosing schedule.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Leukeran is supplied as oral tablets that are swallowed whole with a glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations.

The most serious risks include severe myelosuppression leading to infections, anemia or bleeding; secondary malignancies such as therapy‑related leukemia; pulmonary toxicity; and hemorrhagic cystitis. Patients should report signs of fever, unusual bruising, persistent cough or blood in urine promptly.

Leukeran should not be used by individuals with known hypersensitivity to chlorambucil or other alkylating agents, patients with severe bone‑marrow suppression, active uncontrolled infections, or those who are pregnant unless the benefit outweighs the risk. Caution is also advised for patients with significant hepatic or renal impairment.